Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-9574?

AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer.

Apr 17, 2024 - 00:00
AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Novartis’s XXB...

Next Article

Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: STAT readers on teaching medical students about intellectual disabilities, sobering centers, and annual wellness visits

Opinion: STAT readers on teaching medical students abou...

Dec 17, 2023

HUTCHMED concludes FDA rolling submission for colorectal cancer treatment

HUTCHMED concludes FDA rolling submission for colorecta...

Apr 3, 2023

STAT+: Biotech launches with $82 million for Parkinson’s cell therapy

STAT+: Biotech launches with $82 million for Parkinson’...

Feb 29, 2024